Evaluation of corticotropin releasing factor stimulation and basal markers of hypothalamic-pituitary-adrenal axis suppression in asthmatic patients

Chest

Volumn 112, Issue 5, 1997, Pages 1248-1252

  Clark, D J ^a   Lipworth, Brian J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Asthma; Basal markers; Corticotropin releasing factor; Hypothalamic pituitary adrenal axis suppression; Inhaled budesonide

Indexed keywords

BUDESONIDE; CORTICOTROPIN RELEASING FACTOR; HYDROCORTISONE; PLACEBO;

ADULT; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INHALATIONAL DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030670529     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.112.5.1248     Document Type: Article

References (13)

1. Hanania NA, Chapman KR, Kesten S. Adverse effects of inhaled corticosteroids. Am J Med 1995; 98:196-208
2. Clark DJ, Grove A, Cargill RI, et al. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax 1996; 51:262-66
3. Grove A, Allam C, McFarlane LC, et al. A comparison of the systemic bioactivity of inhaled budesonide and fluticasone propionate in normal subjects. Br J Clin Pharmacol 1994; 38:527-32
4. Brown PH, Blundell G, Greening AP, et al. Screening for hypothalamo-pituitary-adrenal axis suppression in asthmatics taking high dose inhaled corticosteroids. Respir Med 1991; 85:511-16
5. Schlaghecke R, Kornely E, Santen RT, et al. The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone. N Engl J Med 1992; 326:226-330
6. Abbott M, Khoo SH, Hammer MR, et al. Prevalence of cortisol deficiency in late HIV disease. J Infect 1995; 31:1-4
7. Honour JW. Hypothalamic-pituitary-adrenal axis. Respir Med 1994; 88(suppl A):9-15
8. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987; 136:225-43
9. Jennings BH, Andersson KE, Johansson SA. Assessment of the systemic effects of inhaled glucocorticosteroids: comparison of the effects of inhaled budesonide and oral prednisolone on adrenal function and markers of bone turnover. Eur J Clin Pharmacol 1991; 49:77-82
10. Lipworth BJ. New perspectives on inhaled drug delivery and systemic bioactivity. Thorax 1995; 50:105-10
11. Ayres JG, Bateman ED, Lundback B, et al. High dose fluticasone propionate, 1 mg daily, versus fluticasone propionate, 2 mg daily, or budesonide, 1.6 mg daily, in patients with chronic severe asthma. Eur Respir J 1995; 8:579-86
12. Fabbri L, Burge PS, Croonenborgh L, et al. Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for 1 year. Thorax 1993; 48:817-23
13. Broide J, Soferman R, Kivity S, et al. Low-dose adrenocorticotropin test reveals impaired adrenal function in patients taking inhaled corticosteroids. J Clin Endocrinol Metab 1995; 80:1243-45